Caricamento quotazioni...

Previsioni

Il prezzo obiettivo medio degli analisti è 68,04 € (+118,50%). La mediana è 68,04 € (+118,50%).

Acquista	6
Mantieni	0
Vendi	0

Discussioni nella community

Non ci sono ancora discussioni su questo asset.

Avvia discussione

Notizie Vai al feed delle notizie

Maze Therapeutics: pipeline with MZE829 and MZE782 faces pivotal clinical data

Maze Therapeutics reported at the H.C. Wainwright conference progress on the APOL1 inhibitor MZE829 (Phase II HORIZON) and the PKU candidate MZE782. The company expects final HORIZON data by end‑2024/early‑2025 and plans to launch a registration‑enabling MZE829 program in H1 2025; a Phase II start for MZE782 in CKD is also planned for H1 2025, with top‑line PKU data expected in 2027. Early data show an average UACR reduction of 36% (50% responder rate) for MZE829 and a 42‑fold increase in urinary Phe excretion with MZE782; further development steps will depend largely on upcoming data, biomarker analyses and PARSOL‑Shield recommendations. » Altro su de.investing.com
Maze Therapeutics shows encouraging early data for MZE829 and MZE782, pivotal tests still pending

Maze Therapeutics presented early clinical signals at the Citigroup Biopharma Summit: the lead APOL1 program MZE829 showed a mean UACR reduction of 36% in 12 evaluable patients, with particularly strong effects in the FSGS subgroup. The PKU program MZE782 recorded a 42-fold increase in urinary phenylalanine excretion in Phase I and is already in Phase II. Management emphasized that key approval decisions, study-design discussions with the FDA and final HORIZON data are still outstanding; financial figures were not disclosed. » Altro su de.investing.com
Maze Therapeutics appoints Dr. Paula Johnson and Dr. Sophie Kornowski to the board

Maze Therapeutics has appointed Dr. med. Paula Johnson and Dr. pharm. Sophie Kornowski to its board of directors. Johnson brings more than 30 years of experience in clinical cardiology and research as well as leadership roles in academia and oversight bodies; Kornowski has over 35 years of executive experience in the biopharma industry, most recently as CEO of Boston Pharmaceuticals. The clinical biopharma company develops small‑molecule precision medicines for kidney and metabolic diseases and expects additional data on MZE829 in late 2026/early 2027 as well as initial data on MZE782 in 2027. » Altro su de.investing.com

Dati finanziari dell'azienda

Nell'ultimo trimestre, Maze Therapeutics ha registrato ricavi pari a 0 € e un utile netto di -42,35 Mln €

(EUR)	settembre 2026	YoY
Ricavi	0	-
Utile lordo	0	-
Utile netto	-42,35 Mln	65,18%
EBITDA	-41,15 Mln	63,60%

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	1,7 Mld €
Numero di azioni	54,68 Mln
Massimo/minimo a 52 settimane	48,67 € - 19,91 €
Dividendi	No
Beta	2,03
Rapporto P/E	-11,96
Rapporto PEG	0,40
Rapporto P/B	4,88
Rapporto P/S	93,86

Profilo aziendale

Maze Therapeutics, Inc., una società biofarmaceutica in fase clinica, sviluppa medicine di precisione a piccole molecole per il trattamento di malattie renali, cardiovascolari e metaboliche correlate, nonché dell'obesità, negli Stati Uniti. I suoi programmi principali includono MZE829, un inibitore orale a piccola molecola dell'apolipoproteina L1, che si trova in sperimentazione clinica di fase II per il trattamento di pazienti con malattia renale associata ad APOL1; e MZE782, un inibitore orale a piccola molecola del trasportatore di soluti SLC6A19, che si trova in sperimentazione clinica di fase I per il trattamento della malattia renale cronica. Maze Therapeutics, Inc. era precedentemente nota come Modulus Therapeutics, Inc. e ha cambiato denominazione in Maze Therapeutics, Inc. nel settembre 2018. La società è stata costituita nel 2017 e ha sede a South San Francisco, in California.